The results obtained during the MITI2 project will provide a perfectly characterized and GMP-labeled product for cell mediated immunotherapy against IBD. It will hence provide a highly complex and characterized in vitro human preclinical tool for IBD therapies.

The global in vitro testing market

Expected to expand at a compound annual growth rate (CAGR) of 10.7% from 2021 to 2028
stated by a Grand View Research market analysis

Metatissue plans to complete the development and full release of the most promising materials to the market, targeting to maximize the application range of the MITI2 platform, eventually supported by some of the MITI2 partners positioned as Knowledge Providers. The human based platforms for in vitro testing will be explored as personalized disease models for drug screening or understanding disease mechanisms.

The market of organoid culture

Growing at a CAGR of 22% in 2022

Beonchip’s technology will be patented under MITI2, and the microfluidic device developed here will be commercialized after the ending of the project as a new family of devices dedicated to organoid culture. This new product, unlike anything in the market, will definitely place the SME at the forefront of the field that combines organoid culture and organ-on-chip technology.